Laurent Gilardin
YOU?
Author Swipe
View article: Efficacy and Thrombotic Risk of Thrombopoietin Receptor Agonists for Immune Thrombocytopenia Secondary to Systemic Lupus and Antiphospholipid Syndrome: French Experience With 80 Patients
Efficacy and Thrombotic Risk of Thrombopoietin Receptor Agonists for Immune Thrombocytopenia Secondary to Systemic Lupus and Antiphospholipid Syndrome: French Experience With 80 Patients Open
Only few data are available regarding the efficacy and safety of thrombopoietin receptor agonists (TPO‐RAs) for treating systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS)‐associated immune thrombocytopenia (ITP). We…
View article: Cold Agglutinin Syndrome Secondary to <scp><i>Mycoplasma pneumoniae</i></scp> Infection in Adults: Results From a Large French Observational Study (<scp>MyCOLD</scp> Study)
Cold Agglutinin Syndrome Secondary to <span><i>Mycoplasma pneumoniae</i></span> Infection in Adults: Results From a Large French Observational Study (<span>MyCOLD</span> Study) Open
Mycoplasma pneumoniae ( MP ), primarily a respiratory pathogen, can cause extra‐pulmonary manifestations including cold agglutinin syndrome (CAS). We conducted a national, multicenter, observational, ambispective study to describe the char…
View article: Whole Exome Sequencing of Adult Patients With Evans Syndrome Reveals Pathogenic Variants Associated With Autoimmunity
Whole Exome Sequencing of Adult Patients With Evans Syndrome Reveals Pathogenic Variants Associated With Autoimmunity Open
View article: Clinical, biological, prognostic characteristics of patients with immune-mediated thrombotic thrombocytopenic purpura and Sjögren’s disease
Clinical, biological, prognostic characteristics of patients with immune-mediated thrombotic thrombocytopenic purpura and Sjögren’s disease Open
Objectives The association between immune-mediated thrombotic thrombocytopenic purpura (iTTP) and Sjögren disease (SjD) has been poorly investigated. This study presents the first retrospective cohort of iTTP-SjD aiming to identify risk fa…
View article: Activity of apremilast in a patient with severe pemphigus vulgaris: case report
Activity of apremilast in a patient with severe pemphigus vulgaris: case report Open
Introduction Although the treatment for pemphigus vulgaris (PV) has been revolutionized by the use of rituximab combined with corticosteroids, new effective therapies with a better safety profile are needed. Observation A 67-year-old woman…
View article: Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants
Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants Open
Although tocilizumab treatment in severe and critical coronavirus disease 2019 (COVID-19) patients has proven its efficacy at the clinical level, there is little evidence supporting the effect of short-term use of interleukin-6 receptor bl…
View article: Vasculitis and familial Mediterranean fever: Description of 22 French adults from the juvenile inflammatory rheumatism cohort
Vasculitis and familial Mediterranean fever: Description of 22 French adults from the juvenile inflammatory rheumatism cohort Open
Objective The frequency of vasculitis may be increased in patients with Familial Mediterranean Fever (FMF), according to several studies. Our aim was to assess the characteristics of French adult patients with both diseases. Methods Patien…
View article: COVID-19 critique et anticorps anti-Interféron : série de 11 cas
COVID-19 critique et anticorps anti-Interféron : série de 11 cas Open
View article: Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis
Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis Open
This study provides Class IV evidence that for patients with sIBM, long-term treatment with bimagrumab was safe, well-tolerated, and did not provide meaningful functional benefit. The study is rated Class IV because of the open-label desig…
View article: Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients
Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients Open
View article: Demyelinating polyradiculoneuritis in patients with multiple myeloma: the other side of bortezomib-induced neurotoxicity
Demyelinating polyradiculoneuritis in patients with multiple myeloma: the other side of bortezomib-induced neurotoxicity Open
International audience
View article: Intravenous immunoglobulin mediates anti-inflammatory effects in peripheral blood mononuclear cells by inducing autophagy
Intravenous immunoglobulin mediates anti-inflammatory effects in peripheral blood mononuclear cells by inducing autophagy Open
Autophagy plays an important role in the regulation of autoimmune and autoinflammatory responses of the immune cells. Defective autophagy process is associated with various autoimmune and inflammatory diseases. Moreover, in many of these d…
View article: Identification des épitopes T d’ADAMTS13 chez les patients atteints de Purpura Thrombotique Thrombocytopénique
Identification des épitopes T d’ADAMTS13 chez les patients atteints de Purpura Thrombotique Thrombocytopénique Open
Thrombotic thrombocytopenic purpura (TTP) is a rare and severe disease characterized by auto-antibodies directed against ADAMTS13 (A13), a plasmatic protein involved in haemostasis. The implication of CD4⁺ T cells in the pathogenesis of th…
View article: Ibrutinib and idelalisib in the management of CLL‐associated autoimmune cytopenias: a study from the FILO group
Ibrutinib and idelalisib in the management of CLL‐associated autoimmune cytopenias: a study from the FILO group Open
International audience
View article: Intravenous immunoglobulin induces IL-4 in human basophils by signaling through surface-bound IgE
Intravenous immunoglobulin induces IL-4 in human basophils by signaling through surface-bound IgE Open
View article: Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic Purpura
Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic Purpura Open
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is characterized by severe ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13) deficiency, the presence of anti-ADAMTS13 autoantibodies and a…
View article: Symptomatic muscular sarcoidosis
Symptomatic muscular sarcoidosis Open
This nationwide study of muscular sarcoidosis allowed the identification of 4 patterns of granulomatous myositis, which differed by phenotypes and the clinical course.
View article: Complement C3 is a novel modulator of the anti-factor VIII immune response
Complement C3 is a novel modulator of the anti-factor VIII immune response Open
Development of neutralizing antibodies against therapeutic Factor VIII (FVIII) is the most serious complication of the treatment of hemophilia A. There is growing evidence to show the multifactorial origin of the anti-FVIII immune response…
View article: The ADAMTS13 <sup>1239–1253</sup> peptide is a dominant HLA-DR1-restricted CD4 <sup>+</sup> T-cell epitope
The ADAMTS13 <sup>1239–1253</sup> peptide is a dominant HLA-DR1-restricted CD4 <sup>+</sup> T-cell epitope Open
Acquired thrombotic thrombocytopenic purpura is a rare and severe disease characterized by auto-antibodies directed against "A Disintegrin And Metalloproteinase with Thrombospondin type 1 repeats, 13th member" (ADAMTS13), a plas…
View article: High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody
High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody Open
Cancer can occur in patients with inflammatory myopathies. This association is mainly observed in dermatomyositis, and myositis-specific antibodies have allowed us to delineate patients at an increased risk. Malignancy is also reported in …
View article: Generation of Catalytic Antibodies Is an Intrinsic Property of an Individual’s Immune System: A Study on a Large Cohort of Renal Transplant Patients
Generation of Catalytic Antibodies Is an Intrinsic Property of an Individual’s Immune System: A Study on a Large Cohort of Renal Transplant Patients Open
Renal transplant is the treatment of choice for patients with terminal end-stage renal disease. We have previously identified low levels of catalytic IgG as a potential prognosis marker for chronic allograft rejection. The origin and physi…
View article: Vasculitis associated with familial Mediterranean fever: a study on 16 french adult cases
Vasculitis associated with familial Mediterranean fever: a study on 16 french adult cases Open
Results 16 patients (12H, 4F) with a median age of 41 years [2961] were included. Patients were Sefarad Jews (n=9), Turkish (n=2) and Arabic (n=5). Seven of them had a familial history of FMF, none had a familial history of auto-immune dis…
View article: Intravenous immunoglobulin as clinical immune-modulating therapy
Intravenous immunoglobulin as clinical immune-modulating therapy Open
International audience